(NewsDirect)
MGCPharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) chief commercialofficer Robert Clements speaks to Thomas Warner from Proactive afterthe Europe-based plant-inspired medicine company announced it hassecured a US$1mln order from AMC Pharma for ArtemiC, ananti-inflammatory that is also shown to provide benefits to Covidsufferers. Clements gives an overview of the order and of the ArtemiCproduct, explaining that its "the OTC form of CimetrA, which isunder development as an FDA new drug indication file." In March2023, MGC Pharma revealed that ArtemiC had gained a spot on theNational Drug Code Database as an OTC Unlicensed Drug, approved by theUS FDA. Clements says that "we are pushing on as fast as we canand I think you'll hear more good news about some aspects of oneor more of those products in the weeks and months ahead." MGCPharmaceuticals says on its website that ArtemiC has been tested forsafety and efficacy in a double-blind, placebo-controlled clinicaltrial of 50 patients diagnosed with COVID-19.
ContactDetails
Proactive UK Ltd
+44 20 7989 0813
Copyright (c) 2023 TheNewswire - All rights reserved.